Allspring Global Investments Holdings LLC Sells 26,513 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Allspring Global Investments Holdings LLC decreased its stake in Integra LifeSciences Holdings Co. (NASDAQ:IART) by 37.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 44,314 shares of the life sciences company’s stock after selling 26,513 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Integra LifeSciences were worth $1,930,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in IART. Raymond James & Associates lifted its stake in shares of Integra LifeSciences by 24.5% in the 1st quarter. Raymond James & Associates now owns 40,457 shares of the life sciences company’s stock valued at $2,600,000 after acquiring an additional 7,971 shares during the last quarter. MetLife Investment Management LLC raised its position in Integra LifeSciences by 33.4% in the first quarter. MetLife Investment Management LLC now owns 47,096 shares of the life sciences company’s stock valued at $3,026,000 after purchasing an additional 11,796 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in shares of Integra LifeSciences by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,696 shares of the life sciences company’s stock worth $1,715,000 after purchasing an additional 2,546 shares during the last quarter. Great West Life Assurance Co. Can boosted its holdings in Integra LifeSciences by 8.0% in the first quarter. Great West Life Assurance Co. Can now owns 40,012 shares of the life sciences company’s stock valued at $2,643,000 after acquiring an additional 2,969 shares during the last quarter. Finally, Yousif Capital Management LLC increased its position in Integra LifeSciences by 6.5% during the 1st quarter. Yousif Capital Management LLC now owns 40,207 shares of the life sciences company’s stock valued at $2,584,000 after purchasing an additional 2,466 shares during the period. Institutional investors and hedge funds own 84.78% of the company’s stock.

Integra LifeSciences Stock Down 9.3 %

Shares of NASDAQ:IART opened at $28.68 on Monday. The business’s 50 day moving average is $36.85 and its 200 day moving average is $39.10. Integra LifeSciences Holdings Co. has a 12-month low of $27.85 and a 12-month high of $59.10. The stock has a market cap of $2.25 billion, a price-to-earnings ratio of 34.55, a PEG ratio of 0.86 and a beta of 1.12. The company has a quick ratio of 2.18, a current ratio of 3.45 and a debt-to-equity ratio of 0.94.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The company had revenue of $397.00 million for the quarter, compared to the consensus estimate of $399.30 million. During the same quarter last year, the business posted $0.94 earnings per share. Integra LifeSciences’s revenue was down .3% on a year-over-year basis. On average, sell-side analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IART has been the subject of a number of analyst reports. Truist Financial lowered their target price on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. JMP Securities lowered their target price on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. StockNews.com cut Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Finally, Citigroup upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target for the company in a research note on Wednesday, April 3rd. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $44.89.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.